Drug intelligence / Profile preview

SKB518

Development stage: Phase 2
Lead developer: Kelun-Biotech
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

SKB518 is a novel antibody-drug conjugate (ADC) developed by Sichuan Kelun-Biotech Biopharmaceutical. It is designed to target protein tyrosine kinase 7 (PTK7), a relatively uncommon target in oncology. The drug utilizes proprietary OptiDCTM platform technology and has demonstrated promising efficacy and safety in preclinical studies. Its primary indication is for the treatment of advanced solid tumors, with clinical trials currently ongoing in China at Phase 1. The mechanism of action involves modulation of PTK7, likely through targeted delivery of cytotoxic agents to PTK7-expressing tumor cells.

Targets

PTK7 (Protein tyrosine kinase 7)

Beyond the preview

Go deeper on SKB518.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SKB518.

Explore the full profile